Drug Development
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
FEATURED STORIES
AstraZeneca’s $15 billion pledge to its China operations highlights the country’s advantages. But other regions are also hoping to host more clinical studies.
With Lykos’ regulatory failure now squarely in the rearview mirror, Compass Pathways and Definium are leading what one analyst suspects will be “a very big year for psychedelics.”
Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging field.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
New pandemic guidelines from the CDC nearly eliminates mask-wearing requirement for fully vaccinated people.
Researchers are calling for a “paradigm shift” in indoor ventilation systems to combat COVID-19 and other airborne pathogens.
Sanofi and GSK expect to launch a global pivotal Phase III trial of its COVID-19 vaccine in the coming week.
Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.
Proxalutamide, a selective high-affinity silent antagonist of the androgen receptor, is being developed by Chinese biotech, Kintor Pharmaceutical Limited (9939.HK).
A platform trial is also efficient in that it enables the investigators to share placebo information.
Overall, the researchers claim this “Disinformation Dozen” generate approximately 65% of the anti-vaccine misinformation on these platforms.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
Humanigen reported it had held a meeting with the FDA to discuss plans for filing an EUA for its lenzilumab for hospitalized, hypoxic COVID-19 patients by the end of May.